NY-based Capital Rx, whose software lets employers, unions, and insurers handle claims processing and billing for prescription drugs, raises a $106M Series C
Katie Jennings / Forbes :
Context & Ripple Effects
This 2022 round sits early in Capital Rx's funding arc: the NY company sells software that lets employers, unions, and insurers run prescription drug claims processing and billing themselves rather than through a traditional PBM. The raise follows a similar bet on the benefits-navigation side of pharmacy spend — Rightway's $100M Series C a year earlier for an app helping employees navigate care and pharmacy benefits.
The trajectory since validates the thesis: Capital Rx went on to raise $400M including a $252M Series F, passing $607M in total funding at a $3.25B pre-Series F valuation.
First-order effects
- Capital Rx gains $106M to scale its claims-and-billing platform for employer, union, and insurer clients, directly attacking the PBM's grip on prescription drug administration.
Second-order effects
- Employers and unions shopping for pharmacy benefits gain a software-based alternative whose pitch is transparency on claims and billing, forcing incumbents to defend their opaque rebate economics.
- The same automation wave is spreading across healthcare admin — Candid Health's later $120M Series D for AI agents automating medical billing and claims shows investors funding the pattern on the medical side too.
Third-order effects
- If the pattern holds, the administrative plumbing of drug pricing — claims adjudication, billing, benefit design — consolidates into venture-backed software platforms, shifting power over drug spend from intermediaries to the payers who own it.
The trend: Healthcare's administrative middle layers, long controlled by PBMs and manual billing shops, are being rebuilt as venture-backed software platforms.